Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02726581 · ClinicalTrials.gov registry record · Phase 3
An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 170
- Enrollment target
NCT02726581 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 170 participants.
The verdict
NCT02726581, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 170 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of several combination therapies for Multiple Myeloma. Upon entry into the study, patients will be randomized (assigned by chance) to receive either: Group 1: nivolumab, pomalidomide and dexamethasone OR Group 2: pomalidomide and dexamethasone OR Group 3: nivolumab, elotuzumab, pomalidomide and dexamethasone. Enrollment is closed for all groups.
Interventions
- DRUG Dexamethasone
- BIOLOGICAL Nivolumab
- DRUG Pomalidomide
- BIOLOGICAL Elotuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2016-08-10 |
| Est. Completion | 2022-03-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02726581
The ClinicalTrials.gov registry entry for NCT02726581 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Dexamethasone is the first listed.
NCT02726581 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02726581 about?
NCT02726581 is a clinical study titled "An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma". The purpose of this study is to evaluate the safety and effectiveness of several combination therapies for Multiple Myeloma. Upon entry into the study, patients will be randomized (assigned by chance) to receive either: Group 1: nivolumab, pomalidomide and dexamethasone OR Group 2: pomalidomide and...
What is the current status of trial NCT02726581?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 170 participants. The study started on 2016-08-10. Estimated completion is 2022-03-09.
What interventions are being tested in trial NCT02726581?
The interventions under investigation include: Dexamethasone (DRUG), Nivolumab (BIOLOGICAL), Pomalidomide (DRUG), Elotuzumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02726581?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.